The Diagnosis Value of a Novel Model with 5 Circulating miRNAs for Liver Fibrosis in Patients with Chronic Hepatitis B
Open Access
- 1 January 2021
- journal article
- research article
- Published by Wiley in Mediators of Inflammation
- Vol. 2021 (1)
Abstract
Background and Aim. miRNAs play an important role in the development of human fibrosis. However, miRNA expression profiles during different stages of chronic hepatitis B (CHB) are not well defined. In this study, we aimed to further validate the features of 5 miRNA candidates from our previous study during different fibrotic stages and the value of diagnosis for liver fibrosis. Methods. Differential expression of five selected miRNAs (hsa‐mir‐1225‐3p, hsa‐mir‐1238, hsa‐miR‐3162‐3P, hsa‐miR‐4721, and hsa‐miR‐H7) was verified by qRT‐PCR in the plasma of 83 patients and 20 healthy controls. The relative expression of these miRNAs was analyzed in different groups to screen target miRNA. A logistic regression analysis was performed to assess factors associated with fibrosis progression. The receiver operating characteristic (ROC) curve and discriminant analyses validated the ability of these predicted variables to discriminate the nonsignificant liver fibrosis group from the significant liver fibrosis group. Furthermore, the established models were compared with other prediction models to evaluate the diagnostic efficiency. Results. These five tested miRNAs all had signature correlations with hepatic fibrotic level (p < 0.05), and the upregulation trends were consistent with miRNA microarray analysis previously. The multivariate logistic regression analysis identified that a model of five miRNAs (miR‐5) had a high diagnostic accuracy in discrimination of different stages of liver fibrosis. The ROC showed that the miR‐5 has excellent value in diagnosis of fibrosis, even better than the Forns score, FIB‐4, S index, and APRI. GO functions of different miRNAs mainly involved in various biological processes were markedly involved in HBV and revealed signaling pathways dysregulated in liver fibrosis of CHB patients. Conclusions. It was validated that the combination of these five miRNAs was a new set of promising molecular diagnostic markers for liver fibrosis. The diagnosis model (miR‐5) can distinguish significant and nonsignificant liver fibrosis with high sensitivity and specificity.Keywords
Funding Information
- Wenzhou Municipal Science and Technology Bureau (Y20190526)
This publication has 32 references indexed in Scilit:
- MicroRNA Profile in Peripheral Blood Mononuclear Cells from Hepatitis B Virus Infected PatientsAnnals of Hepatology, 2018
- Circulating microRNAs as predictive biomarkers for liver disease progression of chronic hepatitis C (genotype‐4) Egyptian patientsJournal of Medical Virology, 2018
- Serum levels of miRNA in patients with hepatitis B virus-associated acute-on-chronic liver failureHepatobiliary & Pancreatic Diseases International, 2018
- Serum microRNA profiles as diagnostic biomarkers for HBV‐positive hepatocellular carcinomaLiver International, 2017
- MicroRNA panels as disease biomarkers distinguishing hepatitis B virus infection caused hepatitis and liver cirrhosisScientific Reports, 2015
- Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013The Lancet, 2015
- Changes in microRNA expression during disease progression in patients with chronic viral hepatitisLiver International, 2014
- Serum levels of tissue inhibitor of metalloproteinase‐1 are correlated with liver fibrosis in patients with chronic hepatitis BJournal of Digestive Diseases, 2012
- Noninvasive Tools to Assess Hepatic Fibrosis: Ready for Prime Time?Gastroenterology Clinics of North America, 2011
- Molecular Testing in the Diagnosis and Management of Chronic Hepatitis BClinical Microbiology Reviews, 2007